EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
01 marzo 2022
Preclinical Studies With ONC201/TIC10 and Lurbinectedin as a Novel Combination Therapy in Small Cell Lung Cancer (SCLC)
